Company code: Shanghai Rightongene Biotechnology Co.Ltd(688217) company abbreviation: Shanghai Rightongene Biotechnology Co.Ltd(688217) Shanghai Rightongene Biotechnology Co.Ltd(688217)
Annual report for 2021
Important tips
1、 The board of directors, board of supervisors, directors, supervisors and senior managers of the company guarantee the authenticity, accuracy and integrity of the contents of the annual report, and there are no false records, misleading statements or major omissions, and bear individual and joint legal liabilities. 2、 Unprofitable and unprofitable when the company is listed □ yes √ no III. tips on major risks
The company has described the possible risks in this report. Please refer to "IV. risk factors" in "section III Management Discussion and analysis" for investors' attention to investment risks. 4、 All directors of the company attended the board meeting. 5、 Zhonghui Certified Public Accountants (special general partnership) issued a standard unqualified audit report for the company. 6、 Xiong Hui, the person in charge of the company, Li Yan, the person in charge of accounting, and Li Yan, the person in charge of the accounting organization (Accounting Supervisor), declare that they guarantee the authenticity, accuracy and completeness of the financial report in the annual report. 7、 The profit distribution plan or the plan of converting accumulation fund into share capital in the reporting period adopted by the resolution of the board of directors
Fully considering that the company is currently in a period of rapid development, R & D projects, fixed asset investment and marketing network are expanding, and the capital demand is large, in order to better safeguard the long-term interests of all shareholders and ensure the sustainable development and capital demand of the company, the company plans not to distribute cash dividends, bonus shares, transfer capital reserve into share capital and other forms of distribution in 2021, and the remaining undistributed profits will be accumulated to the next year. The above profit distribution plan has been deliberated and approved at the fourth meeting of the second board of directors and the fourth meeting of the second board of supervisors, and needs to be submitted to the 2021 annual general meeting of shareholders of the company for deliberation. 8、 Whether there are important matters such as special arrangements for corporate governance □ applicable √ not applicable IX. risk statement of forward-looking statements √ applicable □ not applicable
The company's future plans, development strategies and other forward-looking statements involved in this report do not constitute the company's substantive commitment to investors. Please pay attention to investment risks. 10、 Is there any non operational occupation of funds by the controlling shareholders and their related parties? No
11、 Whether there is any external guarantee in violation of the specified decision-making procedures? No 12. Whether more than half of the directors cannot guarantee the authenticity, accuracy and integrity of the annual report disclosed by the company? No 13. Others □ applicable √ not applicable
catalogue
Section 1 interpretation Section 2 company profile and main financial indicators Section III Management Discussion and Analysis Section IV corporate governance Section V environment, social responsibility and other corporate governance 80 section VI important matters Section VII changes in shares and shareholders 121 Section VIII preferred shares Section IX corporate bonds Section x financial report one hundred and thirty-three
Financial statements containing the signatures and seals of the person in charge of the company, the person in charge of accounting work and the person in charge of accounting organization (Accounting Supervisor).
The catalogue of documents for future reference contains the original audit report sealed by the accounting firm and signed and sealed by the certified public accountant.
The originals of all company documents and announcements publicly disclosed on the website designated by the CSRC during the reporting period.
Section I interpretation
1、 Interpretation in this report, unless the context otherwise requires, the following words have the following meanings: Interpretation of common words
The company, the company and ruiang refer to Shanghai Rightongene Biotechnology Co.Ltd(688217)
Gene, Inc
Yuanqi biology refers to Shanghai Yuanqi Biomedical Technology Co., Ltd., a wholly-owned subsidiary of the company
Yuntai biology refers to Suzhou Yuntai Biomedical Technology Co., Ltd., a wholly-owned subsidiary of the company
Baitai gene refers to Wuhan Baitai Gene Engineering Co., Ltd., a wholly-owned subsidiary of the company
Siteide biology refers to Shanghai siteide Biotechnology Co., Ltd., a holding subsidiary of the company
Shanghai siteide refers to Shanghai siteide medical laboratory Co., Ltd., a holding subsidiary of the company
Beijing siteide refers to siteide precision (Beijing) medical laboratory Co., Ltd., a holding subsidiary of the company
Wuhan siteide refers to Wuhan siteide medical laboratory Co., Ltd., a holding subsidiary of the company
Jite biotechnology refers to Changchun Jite Biotechnology Co., Ltd., a holding subsidiary of the company
Ruiang Yuntai refers to Shanghai ruiang Yuntai Biomedical Technology Co., Ltd., a wholly-owned subsidiary of the company
Akonni refers to akonni biosystems, Inc. (iconI biosystems), a company in which the company participates
BOCI investment refers to Shanghai BOCI investment partnership (limited partnership), the shareholder of the company
Liyang investment refers to Shanghai Liyang investment partnership (limited partnership), the shareholder of the company
Zhejiang great health refers to the equity investment fund (limited partnership) of Zhejiang great health industry, the shareholder of the company
Chenhe investment refers to Shanghai Chenhe Investment Center (limited partnership), the shareholder of the company
Chenzhide investment refers to Suzhou chenzhide investment partnership (limited partnership), the shareholder of the company
Chende investment refers to Hangzhou Chende investment partnership (limited partnership), the shareholder of the company
Ruihong investment refers to Hangzhou Ruihong investment partnership (limited partnership), the shareholder of the company
Chongqing Ruian refers to Chongqing gaotejia Ruian equity investment fund partnership (limited partnership), the shareholder of the company
Kangshiyunda refers to Tianjin kangshiyunda medical technology development partnership (limited partnership), the shareholder of the company
Lianjing investment refers to Shanghai Lianjing investment management center, the shareholder of the company
Houyang Tianli refers to Houyang Tianli equity investment center (limited partnership) of Ningbo Meishan free trade port area, the shareholder of the company
Houyang Tianhao refers to Houyang Tianhao equity investment center (limited partnership) of Ningbo Meishan free trade port area, the shareholder of the company
Houyang Qihang refers to Suzhou Houyang QIHANG Investment Center (limited partnership), the shareholder of the company
Fengning partnership refers to Tibet Equity Investment Co., Ltd
Beixin investment refers to Hangzhou Beixin equity investment fund partnership (limited partnership), the shareholder of the company
Shanghai Qinyu refers to Shanghai Qinyu enterprise management partnership (limited partnership), the shareholder of the company
Fusion century refers to Wuhan fusion Century Investment Co., Ltd., the shareholder of the company
Shanghai Jinpu refers to Shanghai Jinpu guodiao M & A equity investment fund partnership (limited partnership), the shareholder of the company
Nanjing xiangshengrui Investment Management Center (general partnership), shareholder of the company
Jiaxing Lingfeng refers to Jiaxing Lingfeng equity investment partnership (limited partnership), the shareholder of the company
In vitro diagnosis and IVD refer to invitrodiagnostics, Chinese Name: in vitro diagnosis: reagents, instruments and systems that collect, prepare and test human samples, and diagnose diseases or other human States, including human health conditions, through them for treatment, mitigation, treatment Provide information for the prevention of diseases and their complications
Category I filing and category I refer to the classification of in vitro diagnostic reagent products into category I, category II and category III according to the level of product risk in accordance with the measures for the administration of in vitro diagnostic reagent registration (Order No. 5 of the General Administration of food and Drug Administration for the filing of medical devices).
The first category is the medical devices with low risk. The implementation of routine management can ensure their safety and effectiveness, and the filing management shall be implemented
Class II Registration Certificate and class II refers to the classification of in vitro diagnostic reagent products into class I, class II and class III according to the level of product risk in accordance with the measures for the administration of in vitro diagnostic reagent registration (Order No. 5 of the General Administration of registration certificate of medical devices under the state food and Drug Administration). The second category is medical devices with moderate risk and need to be strictly controlled and managed to ensure their safety and effectiveness, and registration management shall be implemented
The third kind of registration certificate and the third kind of registration certificate refer to the classification of in vitro diagnostic reagent products into class I, class II and class III according to the measures for the administration of in vitro diagnostic reagent registration (Order No. 5 of the General Administration of registration certificate of medical devices under the State Food and Drug Administration) and the level of product risk. The third category is medical devices with high risk and need to take special measures to strictly control and manage them to ensure their safety and effectiveness, and implement registration management
Nmpa and the State Food and Drug Administration refer to the State Drug Administration
The third-party medical laboratory refers to the independent medical laboratory, also known as the third-party medical laboratory or medical independent laboratory or third-party laboratory room. It refers to the medical institution with independent legal personality specializing in medical testing under the permission of the health administrative department. It establishes business cooperation with hospitals to collect and test samples collected by cooperative hospitals; After the test, send the test results to the hospital for clinical application
Molecular diagnosis refers to the application of molecular biological methods to make qualitative or quantitative analysis of various biological molecules of exogenous (viral DNA, etc.) or endogenous (human gene) in the subject, so as to determine their structure or expression level, so as to make diagnosis
Immunodiagnosis refers to the technology used for the detection of infectious diseases, endocrine, tumors and drugs through the immune reaction of antigen and antibody
Biochemical diagnosis refers to the technology used in conjunction with biochemical analysis instruments to determine biochemical indexes in vivo through various biochemical reactions or immune reactions
PCR refers to polymerasechainreaction, Chinese Name: polymerase chain reaction, which can rapidly amplify the target DNA under the catalysis of DNA polymerase. It is a DNA amplification technology
Gene sequencing means that gene sequencing can accurately identify the nucleotide sequence of each site of the target gene by fluorescent labeling the four nucleotides of the DNA sequence respectively. This technology can be used to detect unknown gene sequences. For example, the human genome project is based on the next-generation gene sequencing technology
